Please ensure Javascript is enabled for purposes of website accessibility

Why Geron Corporation's Stock Is Heading Higher Today

By George Budwell – Apr 17, 2018 at 1:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron's experimental blood cancer drug remains a top priority for the pharma behemoth Johnson & Johnson.

What happened

Geron Corporation (GERN 0.42%) is continuing its hyper-volatile ways today, with its shares rising by as much as 10% in early morning trading. What's sparking this rally?

The biotech's stock is responding positively to the news that Johnson & Johnson (JNJ 1.48%) listed the experimental blood cancer drug imetelstat as a top product candidate in its latest pharma pipeline update. This pipeline update was rolled out as part of J&J's first-quarter earnings release before the opening bell today.

Geron and J&J are co-developing the drug as a potential treatment for the bone marrow disorders myelofibrosis and myelodysplastic syndromes.

Human cancer cell.

Image Source: Getty Images.

Despite this early double-digit rally, Geron's shares have cooled off a bit in the interim, and were up by only 3.98%, as of 12:25 p.m. EDT. 

So what

If imetelstat is the real deal, Geron is arguably a downright steal at current levels. Short-sellers, however, apparently think that imetelstat is destined to fail, which explains why they have continued to pile into this speculative biotech in recent months. But with J&J showing no signs of walking away from this collaboration, short-sellers may want to reassess their outlook.  

Now what

The fascinating part of this story is that J&J and Geron should have a really good handle on whether this drug works or not. Imetelstat's third internal review has been completed, and these are not placebo-controlled, double-blind trials, after all. 

Moreover, the type of bone marrow ailments exhibited by these patients do not spontaneously resolve. In fact, it's quite the opposite. So if these patients are showing signs of improving hematological and/or bone marrow characteristics, it can be taken as direct evidence that imetelstat is the underlying cause. 

All things considered, Geron is a far less risky blood cancer play than it was just a few months ago -- especially after J&J's decision to continue highlighting imetelstat as a top product candidate. 

George Budwell owns shares of Geron. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
GERN
$2.38 (0.42%) $0.01
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.62 (1.48%) $2.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.